Lexicon Pharmaceuticals (NASDAQ:LXRX) Posts Quarterly Earnings Results

Lexicon Pharmaceuticals (NASDAQ:LXRX) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01), Zacks reports. Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 39.56%. The firm had revenue of $0.69 million during the quarter, compared to the consensus estimate of $3.99 million.

Here are the key takeaways from Lexicon Pharmaceuticals’ conference call:

• SONATA-HCM enrollment was completed significantly ahead of plan, with the Phase 3 trial including both obstructive and non-obstructive HCM patients. Lexicon expects top-line results in the first quarter of 2027.
• Lexicon expects to satisfy the FDA’s requirements for a ZYNQUISTA (sotagliflozin) resubmission after Steno-1 reaches the required exposure level by the end of August; the company currently anticipates filing the NDA in the fourth quarter of 2026. DKA rates in Steno-1 remain similar to standard of care and below prior inTandem-trial levels.
• Second-quarter revenue fell to $0.7 million from $28.9 million a year earlier, largely because the prior-year period included $27.5 million in Novo Nordisk licensing revenue. Lexicon reported a $31.8 million net loss, versus net income of $3.3 million in the prior-year quarter, while R&D spending increased due to SONATA.
• Lexicon strengthened its liquidity, ending June with $190.6 million in cash and short-term investments and replacing its prior debt with a Hercules Capital facility that provided $55 million at closing, with up to $45 million more potentially available subject to conditions.
• Novo Nordisk continues to advance LX9851, Lexicon’s first-in-class oral ACSL5 inhibitor for obesity, in Phase 1 development. Lexicon could receive another $10 million milestone payment later this year.

Lexicon Pharmaceuticals Stock Performance

Shares of Lexicon Pharmaceuticals stock traded up $0.11 during trading hours on Friday, reaching $2.47. The company had a trading volume of 3,085,741 shares, compared to its average volume of 2,836,652. Lexicon Pharmaceuticals has a one year low of $1.02 and a one year high of $2.68. The business has a fifty day simple moving average of $2.20 and a 200 day simple moving average of $1.86. The company has a debt-to-equity ratio of 0.24, a current ratio of 18.80 and a quick ratio of 18.77. The firm has a market cap of $1.10 billion, a PE ratio of -16.47 and a beta of 1.08.

Key Stories Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Lexicon completed enrollment in the pivotal Phase 3 SONATA-HCM study of sotagliflozin for hypertrophic cardiomyopathy, exceeding its 500-patient enrollment target. Top-line results remain expected in the first quarter of 2027, providing a potentially significant future catalyst. Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
• Positive Sentiment: The company said its activities to resubmit the ZYNQUISTA NDA for glycemic control in adults with type 1 diabetes are nearing completion, with resubmission anticipated in the fourth quarter of 2026. Phase 1 development of obesity candidate LX9851 is also continuing through partner Novo Nordisk, and Lexicon could receive an additional $10 million milestone payment as early as later this year. Lexicon Pharmaceuticals Q2 2026 Earnings Call Transcript
• Positive Sentiment: Lexicon reported $190.6 million in cash and investments at June 30, supported by $96.2 million in stock-sale proceeds, giving it additional resources to fund clinical development. A Hercules Capital facility also provides up to $100 million in potential financing, subject to conditions.
• Neutral Sentiment: Management emphasized disciplined capital allocation and early commercial planning for its late-stage pipeline. However, the principal value drivers remain dependent on successful clinical results and regulatory approval.
• Negative Sentiment: Second-quarter revenue fell to approximately $0.7 million from $28.9 million a year earlier because the prior-year period included substantial Novo Nordisk licensing revenue. The company posted a net loss of roughly $31.8 million, or $0.07 per share, versus net income of $3.3 million in the prior-year quarter. Revenue also came in below analyst expectations, while research and development spending rose to $17.4 million as SONATA-HCM costs increased. Lexicon Pharmaceuticals Reports Q2 Loss, Lags Revenue Estimates

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in Lexicon Pharmaceuticals by 80.1% in the third quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 25,707 shares in the last quarter. Security National Bank of Sioux City Iowa IA bought a new stake in Lexicon Pharmaceuticals during the fourth quarter valued at approximately $31,000. Hudson Bay Capital Management LP purchased a new position in Lexicon Pharmaceuticals in the 2nd quarter worth approximately $26,000. EntryPoint Capital LLC purchased a new position in Lexicon Pharmaceuticals in the 4th quarter worth approximately $39,000. Finally, Cerity Partners LLC increased its holdings in shares of Lexicon Pharmaceuticals by 21.1% in the 2nd quarter. Cerity Partners LLC now owns 206,279 shares of the biopharmaceutical company’s stock worth $195,000 after buying an additional 35,892 shares during the last quarter. 74.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LXRX has been the subject of several recent research reports. Wall Street Zen lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Zacks Research downgraded shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Weiss Ratings upgraded shares of Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Finally, Citigroup lifted their target price on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a research note on Monday, May 11th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $4.55.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.